WO2003083442A3 - Life sciences business systems and methods - Google Patents

Life sciences business systems and methods Download PDF

Info

Publication number
WO2003083442A3
WO2003083442A3 PCT/US2003/009832 US0309832W WO03083442A3 WO 2003083442 A3 WO2003083442 A3 WO 2003083442A3 US 0309832 W US0309832 W US 0309832W WO 03083442 A3 WO03083442 A3 WO 03083442A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
life sciences
business systems
sciences business
haplotype blocks
Prior art date
Application number
PCT/US2003/009832
Other languages
French (fr)
Other versions
WO2003083442A2 (en
Inventor
Bradley A Margus
David R Cox
Stephen P A Fodor
Original Assignee
Perlegen Sciences Inc
Bradley A Margus
David R Cox
Stephen P A Fodor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perlegen Sciences Inc, Bradley A Margus, David R Cox, Stephen P A Fodor filed Critical Perlegen Sciences Inc
Priority to JP2003580832A priority Critical patent/JP2005521930A/en
Priority to AU2003226153A priority patent/AU2003226153A1/en
Priority to EP03745674A priority patent/EP1490519A4/en
Publication of WO2003083442A2 publication Critical patent/WO2003083442A2/en
Publication of WO2003083442A3 publication Critical patent/WO2003083442A3/en

Links

Classifications

    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q99/00—Subject matter not provided for in other groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

Improved life sciences business systems and methods are disclosed. One or more genomes are scanned for single nucleotide polymorphisms. The polymorphisms are assigned to haplotype blocks, and representative SNPs from the haplotype blocks are used in association studies for pharmaceutical and diagnostic developments.
PCT/US2003/009832 2002-03-26 2003-03-26 Life sciences business systems and methods WO2003083442A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2003580832A JP2005521930A (en) 2002-03-26 2003-03-26 Life Science Business System and Method
AU2003226153A AU2003226153A1 (en) 2002-03-26 2003-03-26 Life sciences business systems and methods
EP03745674A EP1490519A4 (en) 2002-03-26 2003-03-26 Life sciences business systems and methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/107,508 2002-03-26
US10/107,508 US7135286B2 (en) 2002-03-26 2002-03-26 Pharmaceutical and diagnostic business systems and methods

Publications (2)

Publication Number Publication Date
WO2003083442A2 WO2003083442A2 (en) 2003-10-09
WO2003083442A3 true WO2003083442A3 (en) 2004-02-05

Family

ID=28452655

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/009832 WO2003083442A2 (en) 2002-03-26 2003-03-26 Life sciences business systems and methods

Country Status (5)

Country Link
US (2) US7135286B2 (en)
EP (1) EP1490519A4 (en)
JP (1) JP2005521930A (en)
AU (1) AU2003226153A1 (en)
WO (1) WO2003083442A2 (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7175679B2 (en) * 2001-03-29 2007-02-13 Biotempt B.V. Oligopeptide treatment of NF-κB mediated inflammation
US20030220258A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US20040202645A1 (en) * 2003-04-08 2004-10-14 Khan Nisar Ahmed Administration of gene-regulatory peptides
US6921751B1 (en) * 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
EP1138692A1 (en) * 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments of human chorionic gonadotropin (hcg) as immunoregulator
US8680059B2 (en) 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
US6844315B2 (en) * 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US7576174B2 (en) * 2000-03-29 2009-08-18 Biotempt B.V. Compositions capable of reducing elevated blood urea concentration
EP1300418A1 (en) * 2001-10-04 2003-04-09 Erasmus Universiteit Rotterdam Gene regulation by oligopeptides
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US20050037430A1 (en) * 2000-03-29 2005-02-17 Biotempt B.V. Methods and uses for protein breakdown products
USRE43279E1 (en) 2000-03-29 2012-03-27 Biotemp B.V. Compositions capable of reducing elevated blood urea concentration
US20080026367A9 (en) * 2001-08-17 2008-01-31 Perlegen Sciences, Inc. Methods for genomic analysis
US20030220259A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of neurological disorders
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US20030224995A1 (en) * 2001-12-21 2003-12-04 Khan Nisar Ahmed Treatment of burns
US20030220261A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US7786084B2 (en) 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US20030220260A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
US7501391B2 (en) 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
JP4041842B2 (en) * 2002-01-15 2008-02-06 デジタル・インフォメーション・テクノロジー株式会社 SNP identification method
GB0211750D0 (en) * 2002-05-22 2002-07-03 Ouwehand Willem Abnormal blood conditions
US7563600B2 (en) 2002-09-12 2009-07-21 Combimatrix Corporation Microarray synthesis and assembly of gene-length polynucleotides
US9232077B2 (en) * 2003-03-12 2016-01-05 Qualcomm Incorporated Automatic subscription system for applications and services provided to wireless devices
US7517529B2 (en) * 2003-04-08 2009-04-14 Biotempt B.V. Treatment of type I diabetes
US7425700B2 (en) 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
WO2005030952A1 (en) * 2003-09-30 2005-04-07 Riken Method of analyzing haplotype
US10043170B2 (en) 2004-01-21 2018-08-07 Qualcomm Incorporated Application-based value billing in a wireless subscriber network
US20070122817A1 (en) * 2005-02-28 2007-05-31 George Church Methods for assembly of high fidelity synthetic polynucleotides
JP2008523786A (en) * 2004-10-18 2008-07-10 コドン デバイシズ インコーポレイテッド Method for assembling high fidelity synthetic polynucleotides
EP1840212A1 (en) * 2005-01-19 2007-10-03 Genesys Technologies, Inc. Method of systematic analysis of relevant gene in relevant genome region (including relevant gene/relevant haplotype)
US9185538B2 (en) 2005-05-31 2015-11-10 Qualcomm Incorporated Wireless subscriber application and content distribution and differentiated pricing
AU2006266609C1 (en) 2005-07-05 2011-10-27 Biotempt B.V. Treatment of tumors
US20070039624A1 (en) * 2005-08-18 2007-02-22 Roberts Richard H Patient compliance system and method to promote patient compliance
US9143622B2 (en) 2006-02-17 2015-09-22 Qualcomm Incorporated Prepay accounts for applications, services and content for communication devices
US9185234B2 (en) 2006-02-22 2015-11-10 Qualcomm Incorporated Automated account mapping in a wireless subscriber billing system
EP1864692A1 (en) 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
US20070231805A1 (en) * 2006-03-31 2007-10-04 Baynes Brian M Nucleic acid assembly optimization using clamped mismatch binding proteins
US20070288388A1 (en) * 2006-06-07 2007-12-13 Beth Eckenrode Method of selling plastic material
US20080131887A1 (en) * 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
US20080217002A1 (en) * 2007-03-07 2008-09-11 Floyd Randolph Simonds Sand control screen having a micro-perforated filtration layer
EP2156320A4 (en) * 2007-05-18 2010-12-15 Optimata Ltd Techniques for purposing a new compound and for repurposing a drug
CA2700975A1 (en) * 2007-09-26 2009-04-02 Navigenics, Inc. Methods and systems for genomic analysis using ancestral data
US20090187420A1 (en) * 2007-11-15 2009-07-23 Hancock William S Methods and Systems for Providing Individualized Wellness Profiles
WO2010030929A1 (en) * 2008-09-12 2010-03-18 Navigenics, Inc. Methods and systems for incorporating multiple environmental and genetic risk factors
US20100088112A1 (en) * 2008-10-03 2010-04-08 Katen & Associates, Llc Life insurance funded heroic medical efforts trust feature
US20100167403A1 (en) * 2008-12-30 2010-07-01 Pioneer Hi-Bred International, Inc. Identification and selection of commercial-quality transgenic plant events
EP2636003B1 (en) * 2010-11-01 2019-08-14 Koninklijke Philips N.V. In vitro diagnostic testing including automated brokering of royalty payments for proprietary tests
US8718950B2 (en) 2011-07-08 2014-05-06 The Medical College Of Wisconsin, Inc. Methods and apparatus for identification of disease associated mutations
EP3836149A1 (en) * 2011-11-07 2021-06-16 QIAGEN Redwood City, Inc. Methods and systems for identification of causal genomic variants
US9235686B2 (en) 2012-01-06 2016-01-12 Molecular Health Gmbh Systems and methods for using adverse event data to predict potential side effects
US8751166B2 (en) 2012-03-23 2014-06-10 International Business Machines Corporation Parallelization of surprisal data reduction and genome construction from genetic data for transmission, storage, and analysis
US8812243B2 (en) 2012-05-09 2014-08-19 International Business Machines Corporation Transmission and compression of genetic data
US10353869B2 (en) 2012-05-18 2019-07-16 International Business Machines Corporation Minimization of surprisal data through application of hierarchy filter pattern
US8855938B2 (en) 2012-05-18 2014-10-07 International Business Machines Corporation Minimization of surprisal data through application of hierarchy of reference genomes
USD731510S1 (en) 2012-06-06 2015-06-09 Omicia, Inc. Display screen or portion thereof with a graphical user interface
US8972406B2 (en) 2012-06-29 2015-03-03 International Business Machines Corporation Generating epigenetic cohorts through clustering of epigenetic surprisal data based on parameters
US9002888B2 (en) 2012-06-29 2015-04-07 International Business Machines Corporation Minimization of epigenetic surprisal data of epigenetic data within a time series
US9836576B1 (en) 2012-11-08 2017-12-05 23Andme, Inc. Phasing of unphased genotype data
US9213947B1 (en) 2012-11-08 2015-12-15 23Andme, Inc. Scalable pipeline for local ancestry inference
WO2016049694A1 (en) 2014-09-30 2016-04-07 Genetic Technologies Limited Methods for assessing risk of developing breast cancer
US10395759B2 (en) 2015-05-18 2019-08-27 Regeneron Pharmaceuticals, Inc. Methods and systems for copy number variant detection
EP3701534B1 (en) 2017-10-17 2024-04-10 Invitae Corporation Molecular evidence platform for auditable, continuous optimization of variant interpretation in genetic and genomic testing and analysis
CN117129704A (en) 2019-08-05 2023-11-28 禧尔公司 Systems and methods for sample preparation, data generation, and protein crown analysis
US11817176B2 (en) 2020-08-13 2023-11-14 23Andme, Inc. Ancestry composition determination
WO2023077487A1 (en) * 2021-11-06 2023-05-11 江汉大学 Adenovirus mnp marker combination, primer pair combination, kit and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525464A (en) * 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5972614A (en) 1995-12-06 1999-10-26 Genaissance Pharmaceuticals Genome anthologies for harvesting gene variants
DE1233366T1 (en) 1999-06-25 2003-03-20 Genaissance Pharmaceuticals Method for producing and using haplotype data
AU2000263446A1 (en) 1999-07-13 2001-01-30 Genaissance Pharmaceuticals, Inc. Drug target isogenes: polymorphisms in the interleukin 4 receptor alpha gene
WO2001080156A1 (en) 2000-04-18 2001-10-25 Genaissance Pharmaceuticals, Inc. Method and system for determining haplotypes from a collection of polymorphisms

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PATIL N. ET AL.: "Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21", SCIENCE, vol. 294, 23 November 2001 (2001-11-23), pages 1719 - 1723, XP002965310 *

Also Published As

Publication number Publication date
AU2003226153A1 (en) 2003-10-13
US7135286B2 (en) 2006-11-14
US20040091890A1 (en) 2004-05-13
US20030186244A1 (en) 2003-10-02
JP2005521930A (en) 2005-07-21
EP1490519A4 (en) 2007-07-04
US6955883B2 (en) 2005-10-18
EP1490519A2 (en) 2004-12-29
WO2003083442A2 (en) 2003-10-09
AU2003226153A8 (en) 2003-10-13

Similar Documents

Publication Publication Date Title
WO2003083442A3 (en) Life sciences business systems and methods
HK1086333A1 (en) Comparative genomic hybridization
WO2001047944A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2003057718A3 (en) Genetic analysis systems and methods
WO2000029623A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2002052044A3 (en) Detection of genetic polymorphisms in genes associated with pharmacogenomics
EP1572899A3 (en) The il-1 gene cluster and associated inflammatory polymorphisms and haplotypes
AU2003237586A1 (en) Confidential information sharing system
AU2003251424A1 (en) Electrochemical detection of single nucleotide polymorphisms (snps)
WO2002006294A3 (en) Haplotypes of the mmp13 gene
WO2001077124A3 (en) Haplotypes of the apoa4 gene
AU2003277918A1 (en) Method for detecting single nucleotide polymorphisms on polydimensional microarrays
AU2003244832A1 (en) Polymorphisms in the equine tnf-alpha gene
IL162733A0 (en) Genetic polymorphisms in the preprotachykinin gene
AU2002366709A1 (en) Nucleotide polymorphisms associated with osteoporosis
AU2003210259A1 (en) Method for detecting single nucleotide polymorphisms
WO2000029622A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
AU2003300370A1 (en) Single nucleotide polymorphism detection using nucleotide depletion genotyping
WO2001077129A3 (en) Haplotypes of the apoc1 gene
WO2004020580A8 (en) Single nucleotide polymorphisms diagnostic for schizophrenia
WO2001079240A3 (en) Haplotypes of the rangap1 gene
WO2001079237A3 (en) Haplotypes of the galr1 gene
WO2001038586A3 (en) Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
WO2001090127A3 (en) Haplotypes of the hoxd3 gene
WO2001077131A3 (en) Haplotypes of the bglap gene

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003580832

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003745674

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003745674

Country of ref document: EP